Observations placeholder

Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system by blocking NMDA receptors.

Memantine is marketed under the brands Axura among others. Memantine has been shown to have a modest effect in moderate-to-severe Alzheimer's diseas and in dementia with Lewy bodies. Despite years of research, there is little evidence of effect on mild Alzheimer's disease

Adverse effects

Common adverse drug reactions include confusion, dizziness, drowsiness, headache, insomnia, agitation, and/or hallucinations. Less common adverse effects include vomiting, anxiety, hypertonia, cystitis, and increased libido It has been reported to induce reversible neurological impairment in multiple sclerosis patients, which led to the halt of an ongoing clinical trial Though exceedingly rare, extrapyramidal side effects (such as dystonic reactions, etc.) may occur, in particular, in the younger population.

 On Dec, 17, 2016 946 people reported to have side effects when taking Memantine Hydrochloride.   Among them, 13 people (1.37%) have Hallucination

Time on Memantine hydrochloride when people have Hallucination  :

Gender of people who have Hallucination when taking Memantine hydrochloride  :

On Dec, 14, 2015: 650 people reported to have side effects when taking Memantine hydrochloride. Among them, 26 people (4.00%) have Death.

Time on Memantine hydrochloride when people have Death  :

Gender of people who have Death when taking Memantine hydrochloride  :